The addition of anthracyclines to adjuvant taxane-based chemotherapy improved survival for certain high-risk patients with ...

SAN ANTONIO -- Women with larger, genomically high-risk breast cancers had significantly lower risk of distant metastasis with chemotherapy that included an anthracycline, a new analysis of a ...

HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy ...

The selection and schedule of treatment should depend on patient preference and toxicity potential, according to Azka Ali, MD.

Data exploring the relationship between hormone-receptor status and benefit from chemotherapy have been inconsistent. Pooled data showed that anthracycline-based polychemotherapy is associated ...

Heart disease is a well-established late effect for pediatric cancer survivors treated with anthracycline chemotherapy. The researchers identified a panel of 27 proteins as biomarkers of ...

Watt said that certain chemotherapy (anthracyclines) have a higher risk of heart failure – up to 15% of the time – and this treatment may be useful to protect the heart. Watt said ...

The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response for certain patients with triple-negative breast cancer. Camrelizumab ...

This analysis found a 5% improvement in distant recurrence–free survival with anthracycline-based chemotherapy, particularly in patients with tumors larger than 2 cm, offering new guidance on ...

The phase 2 trial showed a 42% response rate with lete-cel in synovial sarcoma and MRCLS, with manageable adverse events.